Intercept Pharmaceuticals Stock Price - ICPT

90.87
-0.02 (-0.02%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Intercept Pharmaceuticals Inc ICPT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-4.10 -4.32% 90.89 88.51 92.335 92.00 94.99 20:00:00
Bid Price Ask Price Spread Spread % News
91.00 95.84 4.84 5.05% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,533 738,009 $ 90.71 $ 66,942,281 519,890 56.76 - 125.00
Last Trade Time Type Quantity Stock Price Currency
16:37:38 13 $ 90.87 USD

Intercept Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.98B 32.73M $ -309.24M -10.95 - 31.90M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Intercept Pharmaceuticals News

Loading Messages....

Latest ICPT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ICPT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week94.3498.6988.5195.23346,475-3.45-3.66%
1 Month94.0499.8988.5195.22378,967-3.15-3.35%
3 Months109.70125.0088.51109.49614,608-18.81-17.15%
6 Months62.42125.0056.7692.13553,07228.4745.61%
1 Year95.47125.0056.7689.93648,791-4.58-4.8%
3 Years115.68160.0051.0586.31700,951-24.79-21.43%
5 Years220.65314.9051.05113.52624,074-129.76-58.81%

Intercept Pharmaceuticals Description

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.